The CGHS GLP-1 Guidelines 2026 mark the first time the Central Government Health Scheme (CGHS) has agreed to cover Injection Tirzepatide (Mounjaro) and Injection Semaglutide — two of the most talked-about weight-loss and diabetes drugs in the world — for its beneficiaries. The Ministry of Health & Family Welfare issued the Office Memorandum on 24 July 2026, adding Mounjaro to the CGHS Online List of Restricted Drugs and bringing Semaglutide under the same rulebook.
For any CGHS or Central Services (Medical Attendance) Rules, 1944 [CS(MA)] beneficiary who has watched these injections dominate health headlines while paying ₹13,000 or more a month out of pocket, this looks like good news. It is — but only for a specific slice of beneficiaries. CGHS has built one of its most tightly controlled prescribing frameworks around these two drugs, and most people who simply want help losing weight will not qualify.
📌 Also Read : 8th Pay Commission 2026: Expected Salary, Fitment Factor, Pay Matrix & Latest News
CGHS GLP-1 Coverage – Key Details
| Detail | Information |
|---|---|
| Issuing Authority | Ministry of Health & Family Welfare, EHS Section |
| Order Number | 1-360/18-19/CGHS/MSD (2740767/P)-Part(1611)/EHS(8354138) |
| Date of Issue | 24 July 2026 |
| Effective Date | Immediate |
| Drugs Covered | Injection Tirzepatide (Mounjaro), Injection Semaglutide |
| Applicable To | Eligible CGHS and CS(MA) beneficiaries |
| Key Change | GLP-1 injectables now reimbursable, subject to strict BMI, specialist and monitoring conditions |
Why CGHS Has Moved Now – The Cost and Clinical Pressure Behind This Order
GLP-1 receptor agonists have gone from a niche diabetes drug class to a global phenomenon in barely three years, and India’s pricing tells its own story about why CGHS needed a rulebook before opening the door. Branded Mounjaro currently retails in India between roughly ₹13,125 and ₹25,781 a month depending on dose, while generic Semaglutide has fallen to around ₹1,290 to ₹4,000 a month after patent expiry brought Indian manufacturers into the market. That is a wide enough cost gap, and a large enough beneficiary base, that unrestricted coverage could have strained the scheme significantly.
At the same time, doctors treating CGHS beneficiaries have been fielding requests for these injections for both genuine obesity-linked disease and simple aesthetic weight loss — a distinction the scheme had no formal way to make. Read alongside that pressure, the new guidelines look less like a generous expansion and more like CGHS drawing a firm clinical line before the bill grew unmanageable. That is the context in which the eligibility criteria below need to be read.
📌 Also Read: DA Hike July 2026 – 3% DA Increase confirm for Central Govt Employees
Who Actually Qualifies for Covered Mounjaro or Semaglutide Under CGHS
Coverage is built entirely around Body Mass Index (BMI), not a general diagnosis of obesity. A beneficiary qualifies only if their BMI is 35 kg/m² or higher, with no other condition required. Below that, at a BMI of 32.5 kg/m² or higher, coverage still applies — but only alongside at least one of five specific conditions: Type-2 Diabetes Mellitus that remains uncontrolled despite Metformin and two other oral anti-diabetic drugs, Severe Obstructive Sleep Apnoea, Atherosclerotic Cardiovascular Disease, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), or Chronic Kidney Disease (CKD).
In practice, this rules out the beneficiary who is moderately overweight and wants help shifting a few kilos. CGHS has designed this as a disease-management pathway, not a general weight-management benefit — and that distinction is the single most important thing to understand about the entire order.
The Conditions That Rule You Out Immediately
Even a beneficiary who clears the BMI threshold can be disqualified outright by a set of contraindications the guidelines treat as non-negotiable. A history of pancreatitis rules out therapy, as does any personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia Type-2 (MEN2) — both linked to thyroid tumour risk seen in animal studies of this drug class. Pregnancy and lactation are automatic exclusions, as is Severe Non-Proliferative or Proliferative Diabetic Retinopathy. A history of severe gastroesophageal reflux disease (GERD), gastroparesis, inflammatory bowel disease, or prior metabolic or bariatric surgery closes the door as well.
These are not minor caveats buried in fine print — the guidelines make clear that a “Yes” against any one of these on the specialist certification form means therapy cannot be prescribed at all, regardless of BMI. For a meaningful number of CGHS beneficiaries with diabetes-related eye disease or a history of digestive-tract surgery, this alone will end the conversation before it starts.
📌 Also Read: Expected DA Hike July 2026 – Free Calculator for Central Government Employees
The Three-Month Rule Most Beneficiaries Will Miss
Before a specialist can even consider prescribing Mounjaro or Semaglutide, CGHS requires documented proof that the beneficiary has tried the basics first. The treating specialist must certify that lifestyle modification has been undertaken, dietary counselling has been provided, and a supervised physical activity programme has been followed — and that the beneficiary has stuck with all three for a minimum of three months.
That matters because it means no one walks into a government hospital and walks out with a Mounjaro prescription the same day. The three-month compliance window is a genuine gatekeeping mechanism, not a formality, and beneficiaries hoping for a quick start should plan for this stage to take time.
Who Can Prescribe It — and Why CGHS Made This So Restrictive
CGHS has narrowed prescribing authority to just two categories of doctor: an Endocrinologist or an Internal Medicine Specialist working at a Government Hospital. A general physician, a private CGHS-empanelled doctor outside these specialities, or a Wellness Centre medical officer cannot initiate this therapy. Every prescription must additionally be endorsed by the Head of Department (HoD) of the prescribing specialist — effectively a two-signature system for a single drug category, which is unusually strict even by CGHS standards.
Approval, once granted, is valid for six months only. Continuing beyond that window requires a fresh recommendation from the treating specialist and a fresh HoD endorsement — not an automatic renewal. For Prasar Bharati, defence, and other CGHS-covered central government employees used to longer-validity prescriptions for chronic conditions, this six-month reset is a real behavioural change to plan around.
What Ongoing Treatment Looks Like: Monitoring, Renewal, and the Six-Month Reset
Once therapy begins, CGHS has built in a monitoring schedule that runs for as long as the beneficiary stays on the drug. The first three months require monthly follow-up visits; after that, review shifts to once every three months. At each visit, the specialist is required to document weight reduction, clinical response, gastrointestinal side effects, any evidence of pancreatitis, muscle wasting, and any other adverse drug reaction.
Continuation of treatment is explicitly tied to this documentation — the guidelines state that ongoing therapy depends on “documented clinical benefit and acceptable safety profile,” not simply the beneficiary’s preference to continue. In practical terms, a beneficiary who isn’t showing measurable improvement, or who develops concerning side effects, should expect the specialist to discontinue treatment rather than continue it indefinitely.
What This Actually Looks Like for a CGHS Beneficiary
Consider a 52-year-old CGHS pensioner with a BMI of 34 kg/m², Type-2 diabetes that has stayed poorly controlled despite Metformin and two other oral medicines, and no history of pancreatitis, thyroid disease, or digestive surgery. Under the new rules, this beneficiary clears the 32.5 BMI-plus-comorbidity route. Before any prescription is written, they would need to show three months of documented dietary counselling and supervised activity — likely coordinated through their CGHS Wellness Centre — and then be referred to an Endocrinologist or Internal Medicine Specialist at a government hospital.
If prescribed, the beneficiary gets six months of covered therapy with monthly check-ins for the first quarter, tapering to quarterly visits. At month six, the entire recommendation and HoD endorsement must be redone from scratch if therapy is to continue. It is a workable pathway — but one that demands patience and paperwork at every stage, not a single visit and a prescription pad.
📌 Also Read: Pension Calculator for Central Government Employees – Basic, Family & Commuted
The Real Picture: What This Order Solves, and What It Doesn’t
What this order genuinely delivers is a first, real reimbursement route for two drugs that were previously entirely out-of-pocket for CGHS beneficiaries — a meaningful relief given Mounjaro’s market price of ₹13,000 to over ₹25,000 a month, a sum that would strain most household budgets even at central government pay scales. For beneficiaries managing serious obesity-linked disease rather than casual weight concerns, that is a real and overdue benefit.
What it does not do is create a general-purpose weight-loss pathway. The BMI thresholds, the contraindication list, the three-month lifestyle prerequisite, the narrow prescribing authority, and the six-month renewal cycle together form one of the most tightly gated drug approval processes CGHS currently runs. Anyone hoping this order means Mounjaro is now freely available on a CGHS Wellness Centre prescription slip will be disappointed — this is closer to a hospital-grade disease-management protocol than an easy benefit expansion. Whether CGHS eases these conditions over time, as it has with some other restricted drugs, will depend on how demand and cost trends play out over the coming budget cycles.
Important Links
| What | Link |
|---|---|
| Official Office Memorandum (CGHS GLP-1 Guidelines 2026) | View Order |
| CGHS Official Website | Visit CGHS |
| CGHS Online List of Restricted Drugs | Check Restricted Drug List |
| Central Services (Medical Attendance) Rules, 1944 | Read CS(MA) Rules |
Frequently Asked Questions
Is Mounjaro free under CGHS now?
Not automatically. Injection Tirzepatide (Mounjaro) is covered only for beneficiaries who meet the specified BMI and clinical criteria, have no listed contraindications, and are prescribed by an Endocrinologist or Internal Medicine Specialist with Head of Department endorsement.
Can a CGHS beneficiary get Semaglutide for weight loss alone?
Only if their BMI is 35 kg/m² or higher on its own, or 32.5 kg/m² or higher along with one of the five specified conditions such as uncontrolled Type-2 diabetes or cardiovascular disease. Semaglutide for cosmetic or minor weight loss is not covered.
Which CGHS doctors can prescribe Tirzepatide or Semaglutide?
Only an Endocrinologist or an Internal Medicine Specialist working at a Government Hospital can prescribe these drugs under CGHS, and every prescription must be endorsed by the concerned Head of Department.
What BMI is required for CGHS to cover Mounjaro?
A BMI of 35 kg/m² or above qualifies on its own. A BMI of 32.5 kg/m² or above qualifies only if the beneficiary also has one of five specified conditions, including uncontrolled diabetes, severe sleep apnoea, or chronic kidney disease.
Does CGHS cover Ozempic, or only Mounjaro and Semaglutide?
The Office Memorandum names Injection Tirzepatide (Mounjaro) and Injection Semaglutide specifically. Ozempic is a Semaglutide brand, so the same molecule is covered — but confirm with your CGHS Wellness Centre which specific brand or formulation is procured under the scheme.
How long does CGHS approval for GLP-1 therapy last?
Approval is valid for six months from the date of prescription. Continuing therapy beyond that requires a fresh recommendation from the treating specialist and a new endorsement from the Head of Department.
Summing Up…
The CGHS GLP-1 Guidelines 2026 open a genuine, if narrow, door for beneficiaries battling serious obesity-related disease or difficult-to-control Type-2 diabetes to access Mounjaro and Semaglutide without bearing the full market cost themselves. But this is not a scheme built for convenience — the BMI thresholds, contraindication checklist, three-month lifestyle prerequisite, and six-month renewal cycle mean only beneficiaries who meet strict clinical criteria, and are willing to work through a government hospital specialist, will actually benefit. If you believe you may qualify, the first step is a conversation with your CGHS Wellness Centre medical officer about a referral — not a request for the drug itself.
Bookmark Govtserviceinfo.com and join our Telegram channel for instant alerts on CGHS orders, central government employee benefits, and health scheme updates.
Disclaimer: This article is based on the Ministry of Health & Family Welfare Office Memorandum No. 1-360/18-19/CGHS/MSD(2740767/P)-Part(1611)/EHS(8354138) dated 24 July 2026. Drug pricing figures reflect market data reported as of mid-2026 and are subject to change. All details are subject to official announcements from CGHS and the Ministry of Health & Family Welfare. Govtserviceinfo.com is not affiliated with the Ministry of Health & Family Welfare or CGHS. Readers should verify current information and consult a qualified specialist before making any treatment decisions.
